Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Radiology, the medical specialty into which AI has made the furthest initial inroads in the U.S., is embracing the technology in France. And this is so despite French radiologists feeling underinformed on AI up to now.
Some are calling the first generation whose members will never have known life without smartphones “Generation Alpha.” And some are predicting they’ll be as reliant on AI as Millennials and Generation Z have been on the internet.
The simultaneous advances of deep learning and radiomics may soon yield a single unified framework for clinical decision support that has the potential to “completely revolutionize the field of precision medicine.”
The FDA has given 510(k) clearance to an AI alert for urgent finding of a collapsed lung in chest X-rays. The approval is a first for an AI-based chest X-ray solution that can help doctors make quicker diagnoses from one of the world’s most used imaging modalities.
AI can predict death or heart attack better than humans, according to a new study presented at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC) in Lisbon.
Combing through insurance claims and other health data on more than 72 million U.S. residents, a machine learning algorithm was able to quite accurately identify more than 222,000 individuals who have very early stage Alzheimer’s disease.
As medical devices are increasingly being touched by new AI innovations, the FDA will soon have to grapple with reality of regulating “living things” in a new way, according to a report from Roll Call.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.
As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”
